The results of this general practice study in 248 patients suggest that acetylcysteine (Fabrol) administered orally for 2 months to patients with chronic bronchitis effectively changes the viscosity and character of sputum with resultant ease of expectoration and cough severity. There was a notable improvement in associated abnormal physical signs such as the presence of rhonchi, crepitations and symptoms including dyspnoea at rest. Tolerability was good, with 77% of patients experiencing no side-effects.
Get full access to this article
View all access options for this article.
References
1.
OswaldN CMedveiV CWallerR E (1967) Chronic bronchitis: a 10-year follow-up. Thorax22, 279.
2.
ScottK W (1976) A clinico pathological study of fatal chronic airways obstruction. Thorax31, 693.
3.
SheffnerA LMedlerE MJacobsL WSarettH P (1964) The in vitro reduction in viscosity of human tracheo-bronchial secretions by acetylcysteine. American Review of Respiratory Diseases90, 721.
4.
TattersallA BBridgmanK MHuitsonA (1983) Acetylcysteine (Fabrol) in chronic bronchitis – a study in general practice. The Journal of International Medical Research11, 279.
